Literature DB >> 23602681

Aspirin and heparin to improve live birth rate in IVF for unexplained implantation failure?

David A Clark1.   

Abstract

The data concerning use of aspirin and/or heparin in IVF failure patients is reviewed. A number of methodological and biological problems are identified. A strategy to achieve reliable conclusions is explained.
Copyright © 2013 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23602681     DOI： 10.1016/j.rbmo.2013.03.007

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN： 1472-6483            Impact factor:   3.828


  4 in total

1.  Could empirical low-dose-aspirin administration during IVF cycle affect both the oocytes and embryos quality via COX 1-2 activity inhibition?

Authors:  Salvatore Gizzo; Denise Capuzzo; Cecilia Zicchina; Stefania Di Gangi; Maria Lia Coronella; Alessandra Andrisani; Michele Gangemi; Giovanni Battista Nardelli
Journal:  J Assist Reprod Genet       Date:  2014-01-17       Impact factor: 3.412

2.  An enhanced clot growth rate before in vitro fertilization decreases the probability of pregnancy.

Authors:  A N Balandina; E M Koltsova; T A Teterina; A G Yakovenko; E U Simonenko; A V Poletaev; I V Zorina; A M Shibeko; T A Vuimo; S A Yakovenko; F I Ataullakhanov
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

3.  Precision Medicine in Assisted Conception: A Multicenter Observational Treatment Cohort Study of the Annexin A5 M2 Haplotype as a Biomarker for Antithrombotic Treatment to Improve Pregnancy Outcome.

Authors:  Simon Fishel; Deborah Baker; Janine Elson; Maha Ragunath; Glenn Atkinson; Adel Shaker; Ahmed Omar; Rahnuma Kazem; Ashley Beccles; Ian A Greer
Journal:  EBioMedicine       Date:  2016-07-18       Impact factor: 8.143

Review 4.  Molecular Targets of Aspirin and Prevention of Preeclampsia and Their Potential Association with Circulating Extracellular Vesicles during Pregnancy.

Authors:  Suchismita Dutta; Sathish Kumar; Jon Hyett; Carlos Salomon
Journal:  Int J Mol Sci       Date:  2019-09-05       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.